Showing results (71-80 of 78) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 78 results.
Vaccine|November 11, 2024
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in MexicoConstantino López-Macías, Martha Torres, Brenda Armenta-Copca, et al.
Eclinicalmedicine|March 14, 2022
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
The Lancet. Infectious Diseases|October 22, 2019
Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trialDavid I Bernstein, Jeffrey Guptill, Abdollah Naficy, et al.
Medrxiv : the Preprint Server for Health Sciences|February 16, 2022
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in MexicoSamuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez, et al.
Medrxiv : the Preprint Server for Health Sciences|September 28, 2021
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 TrialPunnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, et al.
NPJ Vaccines|May 10, 2023
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in MexicoSamuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez, et al.
Med (New York, N.Y.)|August 31, 2022
Discovery and intranasal administration of a SARS-CoV-2 broadly acting neutralizing antibody with activity against multiple Omicron subvariantsJ Andrew Duty, Thomas Kraus, Heyue Zhou, et al.
Science Advances|June 27, 2025
Phase 2/3 study evaluating safety, immunogenicity, and noninferiority of single booster dose of AVX/COVID-12 vaccineConstantino López-Macías, Martha Torres, Brenda Armenta-Copca, et al.
Pageof 8